(NASDAQ: CYTK) Cytokinetics's forecast annual revenue growth rate of 55.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 100.47%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.34%.
Cytokinetics's revenue in 2025 is $87,211,000.On average, 22 Wall Street analysts forecast CYTK's revenue for 2025 to be $10,420,273,104, with the lowest CYTK revenue forecast at $8,387,374,129, and the highest CYTK revenue forecast at $19,748,231,332. On average, 20 Wall Street analysts forecast CYTK's revenue for 2026 to be $17,207,566,107, with the lowest CYTK revenue forecast at $6,482,242,006, and the highest CYTK revenue forecast at $30,042,938,354.
In 2027, CYTK is forecast to generate $44,219,556,871 in revenue, with the lowest revenue forecast at $33,395,442,707 and the highest revenue forecast at $62,237,739,458.